Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA (SP-8203-2001)
A Prospective, Randomized, Double-blinded Phase IIa Clinical Trial to Investigate the Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA Standard of Care
Sponsor: Shin Poong Pharmaceutical Co. Ltd.
Listed as NCT02787278, this PHASE2 trial focuses on Ischemic Stroke and remains completed. Sponsored by Shin Poong Pharmaceutical Co. Ltd., it has been updated 9 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 4 earlier versions
-
Feb 2019 — Aug 2020 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Sep 2017 [monthly]
Recruiting PHASE2
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shin Poong Pharmaceutical Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .